Drugs / BP1001-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04196257 | Aug 2022 → Jul 2027 expected | endometrial cancer, fallopian tube neoplasm, malignant epithelial tumor of ovary, peritoneum cancer | Bio-Path Holdings, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-06-03 | Bio-Path Holdings, Inc. | Results Bio-Path Holdings Provides Clinical and Operational Update biopathholdings.com ↗ |
| 2025-05-01 | Bio-Path Holdings, Inc. | Results Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients biopathholdings.com ↗ |
| 2025-03-18 | Bio-Path Holdings, Inc. | Results Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients biopathholdings.com ↗
Bio-Path Holdings, Inc., (OTCQB :BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today reported results from recent preclinical studies of BP1001-A that support its potential as a treatment for obesity. |
| 2025-02-13 | Bio-Path Holdings, Inc. | Results Bio-Path Holdings Provides Key Clinical Updates biopathholdings.com ↗
This elderly female patient with gynecologic cancer had previously been treated with multiple lines of chemo therapy along with multiple surgeries for her disease, and only now is showing positive clinical results with BP1001-A treatment. |
| 2024-12-19 | Bio-Path Holdings, Inc. | Results Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity biopathholdings.com ↗ |
| 2024-08-21 | Bio-Path Holdings, Inc. | Results Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors biopathholdings.com ↗ |
| 2021-10-27 | Bio-Path Holdings, Inc. | Regulatory Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors biopathholdings.com ↗
This IND clearance for prexigebersen-A marks an important regulatory milestone for Bio- Path, as we progress our fourth drug candidate into the clinic. |
All press releases naming this drug 10 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BP1001-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04196257 ↗ |
| Modality | Antisense oligonucleotide | “Liposomal Grb2 Antisense Oligonucleotide” NCT04196257 ↗ |
| Route | Intravenous | “Dose escalation of BP1001-A intravenously (IV)” NCT04196257 ↗ |
| Target | GRB2 | “Grb2 Antisense Oligonucleotide” NCT04196257 ↗ |